

P03-369

**COMPLIANCE TO TREATMENT WITH QUETIAPINE VS QUETIAPINE XR OF 24 PATIENTS WITH DIAGNOSIS OF FIRST EPISODE OF PSYCHOSIS IN SPDC**

**A. Russo**<sup>1</sup>, S. Pirone<sup>2</sup>, N.M. Passione<sup>2</sup>, F. D'Amato<sup>3</sup>, F. Pirarella<sup>3</sup>, F. Fiore<sup>1</sup>

<sup>1</sup>*Dipartimento di Salute Mentale, ASL AV2, Avellino*, <sup>2</sup>*Dipartimento di Neuroscienze, Unità Didattico Scientifica di Psichiatria*, <sup>3</sup>*Dipartimento di Neuroscienze, Area Funzionale di Psichiatria, Università di Napoli "Federico II", Naples, Italy*

**Objective:** To value medication adherence and discontinuation of treatment among first episode psychosis patients (FEP) treated with quetiapine or extended release of quetiapine (XR).

**Method:** Patients with a first episode of psychosis, age 26+/- 2(N=24) were randomly assigned to treatment with quetiapine 300 mg for twice daily( n=12), or quetiapine rp 300mg/day in one administration daily(n=12),for a 6 months period.

**Result:** The drop-out of patients for any cause thought the 6-months study was:2 for quetiapine and 6 for quetiapine XR. However, symptom reduction were the same in both groups.

**To conclude:** According to a interview conducted with patients, there is more compliance to therapy for patients treated with quetiapine XR, they prefer to be given a day instead of twice daily administration. Fewest drop-out with quetiapine XR is probably also due to steady-state quetiapiana rp is reached more quickly and better maintained, resulting in greater clinical control.